ENTA (Enanta Pharmaceuticals) Accounts Payable & Accrued Expense : $21.55 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Accounts Payable & Accrued Expense?

Enanta Pharmaceuticals's quarterly accounts payable & accrued expense increased from Mar. 2024 ($17.36 Mil) to Jun. 2024 ($23.51 Mil) but then declined from Jun. 2024 ($23.51 Mil) to Sep. 2024 ($21.55 Mil).

Enanta Pharmaceuticals's annual accounts payable & accrued expense declined from Sep. 2022 ($26.94 Mil) to Sep. 2023 ($22.44 Mil) and declined from Sep. 2023 ($22.44 Mil) to Sep. 2024 ($21.55 Mil).

Enanta Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Enanta Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Accounts Payable & Accrued Expense Chart

Enanta Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

19.90

31.97

26.94

22.44

21.55

Enanta Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															22.44	20.93	17.36	23.51	21.55

Enanta Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Executives

Scott T. Rottinghaus	officer: Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer	officer: Sr. VP, New Product Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Terry Vance	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu	officer: Sr. VP, Business Dev.	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or	officer: Chief Scientific Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly	director, officer: President and CEO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner	director	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett	officer: Treasurer and CFO	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda	officer: Sr. VP & Chief Medical Officer	C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Yujiro S Hata	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta	director	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901